Fate Therapeutics Inc 2025年度报告

"ôÍŘ ‹ēÍŘôēĺīîôŘŜϠ ͑͏͔͑ſÍŜ Í ƅôÍŘ ĺċ ıôÍIJĖIJČċŪī ŕŘĺČŘôŜŜ ċĺŘ >Íťô “ēôŘÍŕôŪťĖèŜ ÍŜ ſô èĺIJťĖIJŪôîÍîŽÍIJèĖIJČ ĺŪŘ ıĖŜŜĖĺIJ ťĺ æŘĖIJČ ťŘÍIJŜċĺŘıÍťĖŽô èôīīŪīÍŘ ĖııŪIJĺťēôŘÍŕĖôŜ ťĺŕÍťĖôIJťŜ ſĖťē èÍIJèôŘ ÍIJî ÍŪťĺĖııŪIJô îĖŜôÍŜôŜϟ IIJ ıƅ ƱŘŜť ƅôÍŘ ÍŜ (iϠ IċĺèŪŜôî ĺIJ ŜēÍŘŕôIJĖIJČ ĺŪŘ ŜťŘÍťôČĖè ŕŘĖĺŘĖťĖôŜϠ ĖIJŜťĖīīĖIJČ ƱIJÍIJèĖÍī îĖŜèĖŕīĖIJôϠÍIJî ôIJŜŪŘĖIJČ ſô ċŪīīƅ īôŽôŘÍČô ťēô ŜťŘôIJČťē ĺċ ĺŪŘ ŜèĖôIJèôϟ ®ô ŜťŘôÍıīĖIJôîĺŕôŘÍťĖĺIJŜ ÍIJî ŘôîŪèôî ĺŕôŘÍťĖIJČ ôƄŕôIJŜôŜϠ ÍīīĺſĖIJČ ŪŜ ťĺ ôƄťôIJî ĺŪŘ ƱIJÍIJèĖÍīŘŪIJſÍƅ ſēĖīô èĺIJťĖIJŪĖIJČ ťĺ ÍîŽÍIJèô ĺŪŘ ēĖČēôŜťϱŕŘĖĺŘĖťƅ èīĖIJĖèÍī ŕŘĺČŘÍıŜϟ iŪŘċĺèŪŜ ĖŜ èīôÍŘϡ ôƄôèŪťĖIJČ ĺIJ ŜèÍīÍæīôϠ ĺƯϱťēôϱŜēôīċ èôīī ťēôŘÍŕĖôŜ ťēÍť èÍIJôƄŕÍIJî ŕÍťĖôIJť ÍèèôŜŜϟ >“͗͐͘Ϡ ĺŪŘ īôÍî èīĖIJĖèÍī ŕŘĺČŘÍıϠ ĖŜ ÍIJ ĺƯϱťēôϱŜēôīċ "͐͘ϱťÍŘČôťôî 
‡ “ϱèôīī ťēôŘÍŕƅ æôĖIJČ ôŽÍīŪÍťôî ĖIJŕÍťĖôIJťŜ ſĖťē ŜƅŜťôıĖè īŪŕŪŜ ôŘƅťēôıÍťĺŜŪŜ ÍŜ ſôīī ÍŜ ÍîîĖťĖĺIJÍī ÍŪťĺĖııŪIJô îĖŜôÍŜôŜ ĖIJèīŪîĖIJČ ŜƅŜťôıĖèŜèīôŘĺŜĖŜϠ ĖîĖĺŕÍťēĖè ĖIJƲÍııÍťĺŘƅ ıƅĺŕÍťēƅϠ ÍIJî
b
ϱÍŜŜĺèĖÍťôî ŽÍŜèŪīĖťĖŜϟ "ŪŘĖIJČ͑͏͔͑ Ϡ ſô ŜÍſ ŜťŘĺIJČôƄŕÍIJŜĖĺIJ ĺċ èīĖIJĖèÍī ŜĖťôŜ ÍIJî ŕÍťĖôIJť ôIJŘĺīīıôIJť ÍèŘĺŜŜ ťēô >“͗͐͘ ŜťŪîƅĖIJ æĺťē ťēô ˜IJĖťôî ‹ťÍťôŜ ÍIJîĖIJťôŘIJÍťĖĺIJÍīīƅϠ ıĺıôIJťŪı ťēÍť ſô ôƄŕôèť ťĺ èĺIJťĖIJŪô ÍèèôīôŘÍťĖIJČ ĖIJ͑͏͕͑ϟ (ÍŘīƅ èīĖIJĖèÍī ĺæŜôŘŽÍťĖĺIJŜ ŜŪŕŕĺŘť ťēô ŕĺťôIJťĖÍī ċĺŘ >“͗͐͘ ťĺ ŘôîŪèô îĖŜôÍŜô ÍèťĖŽĖťƅ ÍIJî ŘôŜôť ĖııŪIJôċŪIJèťĖĺIJϟ IıŕĺŘťÍIJťīƅϠ ſô ÍèēĖôŽôî Í ħôƅ ĺŕôŘÍťĖĺIJÍī ıĖīôŜťĺIJô æƅ ÍîıĖIJĖŜťôŘĖIJČ >“͗͐͘ ĖIJ ťēô ĺŪťŕÍťĖôIJťŜôťťĖIJČϟ “ēô ÍæĖīĖťƅ ťĺ îôīĖŽôŘ 
‡ “ϱèôīī ťēôŘÍŕƅ ĺŪťŜĖîô ĺċ ŜŕôèĖÍīĖƏôî ĖIJŕÍťĖôIJť ċÍèĖīĖťĖôŜ ŘôŕŘôŜôIJťŜ ÍIJĖıŕĺŘťÍIJť Ŝťôŕ ťĺſÍŘî ĖıŕŘĺŽĖIJČ ŕÍťĖôIJť ÍèèôŜŜϟ ôƅĺIJî >“͗͐͘Ϡ ſô èĺIJťĖIJŪô ÍîŽÍIJèĖIJČ IJôƄťϱČôIJôŘÍťĖĺIJ èôīī ťēôŘÍŕƅ ŕŘĺČŘÍıŜ ÍèŘĺŜŜ ĺŪŘ ŕĖŕôīĖIJô ÍIJî ĺŪŘèĺīīÍæĺŘÍťĖĺIJ ſĖťē iIJĺ „ēÍŘıÍèôŪťĖèÍīϟ >“͕͗͒Ϡ ĺŪŘ aI
ϯϱťÍŘČôťôî 
‡ “ϱèôīī ťēôŘÍŕƅ ċĺŘ ŜĺīĖî ťŪıĺŘŜϠîôıĺIJŜťŘÍťôî ôÍŘīƅ ŜĖČIJŜ ĺċ æĖĺīĺČĖèÍī ÍèťĖŽĖťƅ ĖIJ ĖIJĖťĖÍī èīĖIJĖèÍī ťôŜťĖIJČϠ ŕŘĺŽĖîĖIJČ ôIJèĺŪŘÍČĖIJČ ŽÍīĖîÍťĖĺIJ ĺċ ĺŪŘŕīÍťċĺŘı ĖIJ ĺIJèĺīĺČƅϟ ®ô ÍīŜĺ ŕŘĺČŘôŜŜôî >“͗͒͘Ϡ Í îŪÍīϱťÍŘČôťĖIJČ 
‡ “ϱèôīī ťēôŘÍŕƅ îôŜĖČIJôî ťĺ ŘôèĺČIJĖƏôæĺťē "͐͘ ÍIJî "͒͗Ϡ ſēĖèē ēÍŜ ŜēĺſIJ ŕŘĺıĖŜĖIJČ ŕŘôèīĖIJĖèÍī ÍèťĖŽĖťƅ ÍèŘĺŜŜÍŪťĺĖııŪIJô îĖŜôÍŜôŜ ÍIJîēôıÍťĺīĺČĖè ıÍīĖČIJÍIJèĖôŜϟ
Ŝ ſô īĺĺħ ÍēôÍî ťĺ͑͏͕͑ Ϡ ſô ôƄŕôèť èĺIJťĖIJŪôî ôIJŘĺīīıôIJť ÍIJî èīĖIJĖèÍī ŪŕîÍťôŜ ċŘĺı ťēô >“͗͐͘ ŕŘĺČŘÍı ÍŜſôīī ÍŜ ŘôČŪīÍťĺŘƅ ôIJČÍČôıôIJť ŘôČÍŘîĖIJČ ťēô îôŜĖČIJ ĺċ Í ŘôČĖŜťŘÍťĖĺIJÍī ŜťŪîƅ ĖIJ īŪŕŪŜϟ ®ô ŘôıÍĖIJ èĺııĖťťôîťĺ ÍîŽÍIJèĖIJČ ťēôŘÍŕĖôŜ ťēÍť ÍŘô IJĺť ĺIJīƅ ĖIJIJĺŽÍťĖŽô æŪť ÍīŜĺ ŜèÍīÍæīô ÍIJî ÍèèôŜŜĖæīô ťĺ ťēô ŕÍťĖôIJťŜ ſēĺ IJôôîťēôı ıĺŜťϟ iIJ æôēÍīċ ĺċ ťēô ôIJťĖŘô īôÍîôŘŜēĖŕ ťôÍıϠ I ťēÍIJħ ĺŪŘ ôıŕīĺƅôôŜϠ èĺīīÍæĺŘÍťĺŘŜϠ ÍIJî èīĖIJĖèÍī ĖIJŽôŜťĖČÍťĺŘŜ ċĺŘťēôĖŘ îôîĖèÍťĖĺIJϠ ÍIJî ĺŪŘ ŜēÍŘôēĺīîôŘŜ ċĺŘ ťēôĖŘ èĺIJťĖIJŪôî ŜŪŕŕĺŘťϟ ‹ĖIJèôŘôīƅϠ ĺæ «ÍīÍıôēŘϠ „ēϟ"ϟϠ a
„ŘôŜĖîôIJť ÍIJî ēĖôċ (ƄôèŪťĖŽô iƯĖèôŘ>Íťô “ēôŘÍŕôŪťĖèŜ FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yesնor Noշ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yesշor Noն Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YesշNoն Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growthcompany. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filerնNon-accelerated filerշEmerging growth companyն Accelerated filerնSmaller reporting companyշ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act.ն If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect thecorrection of an error to previously issued financial statements.ն Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of theregistrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).ն Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).YesնNoշ The aggregate market value of the common stock held by non-affiliates of the registrant was approximately $113,000,000 as of June 30, 2025 b